Take advantage of educational resources
Portrazza Resource Center
Access or order educational resources online. Visit the Resource Center to order today.
Presents the analyses and results of the SQUIRE trial, a randomized, multicenter, open-label, phase III, controlled trial of Portrazza (necitumumab) in combination with gemcitabine and cisplatin versus gemcitabine and cisplatin alone in patients receiving initial chemotherapy for their metastatic squamous NSCLC (N=1093). Use your The Lancet® login information to view the publication.
LillyMedical.com is available to all healthcare professionals in the US. This online resource offers Lilly product and medical information, including Prescribing Information, using a self-directed search. Visitors to the site can submit a question or chat with a Lilly Medical Professional. For more information, visit www.LillyMedical.com.
Portrazza Dosing and Administration Guide
Offers detailed information on recommended dose and schedule, premedication, dose modifications, and infusion preparation for Portrazza.
Portrazza Billing and Coding Guide
This guide contains applicable billing and coding information for Portrazza.
Key Information for Claims Submission
This guide contains helpful information, including proper HCPCS, CPT®, NDC, diagnosis codes, and billing units related to submitting claim forms for the administration of Portrazza.
CMS-1450 Sample Claim Form
This resource provides suggested guidance on how to populate the CMS-1450 claim form when submitting a claim for the administration of Portrazza in the outpatient hospital setting.
CMS-1500 Sample Claim Form
This resource provides suggested guidance on how to populate the CMS-1500 claim form when submitting a claim for the administration of Portrazza in the physician’s office.
The Lancet® is a registered trademark of Reed Elsevier Properties S.A.
CPT is a registered trademark of the American Medical Association.
Lilly PatientOne Co-pay Program:
See if your patients qualify
Explore the range of patients included in the SQUIRE trial
Help patients manage their skin and nails during treatment
Explore the results of the SQUIRE trial
Thoracic Treatment Talk:
Watch Ed Kim, MD, FACP, discuss Portrazza, a treatment option for your patients with metastatic squamous NSCLC
Learn more about the recommended dosing and administration of Portrazza
Learn more about dose modifications with Portrazza
Learn more about the incidence of dermatologic toxicities with Portrazza plus gemcitabine and cisplatin
View the incidence of electrolyte abnormalities with Portrazza plus gemcitabine and cisplatin
View the adverse reactions of Portrazza plus gemcitabine and cisplatin
High Unmet Need:
Review the unmet need in first-line squamous NSCLC
A multicenter, phase III trial in 1093 patients
Explore the results of the trial by using your login information at The Lancet®
Find out how Lilly PatientOne may provide financial assistance for eligible patients